The objectives of this prospective non-interventional study are to characterize the existing unmet needs across the spectrum of atopic dermatitis (AD), enhance the understanding of the patient journey, and evaluate the safety and clinical outcomes of systemic AD treatments in a real-world setting. Additionally, patient-specific factors (such as age, skin color, AD flare triggers, previous treatment responses, comorbid conditions, and the extent and site of lesions) will be assessed to better characterize the impact on the treatment journey across a broad age range and diverse geographic regions. The study will be conducted across 10 countries in 4 different geographical regions, with a follow-up period of 5 years.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Number of Participants Utilizing Atopic Dermatitis (AD) Treatment
Timeframe: Baseline to up to 60 months
Duration of Treatment
Timeframe: Baseline to up to 60 months
AD Treatment Sequences
Timeframe: Baseline to up to 60 months
Number of Participants Initiating AD Treatments with Reasons
Timeframe: Baseline to up to 60 months
Number of Participants Interrupting AD Treatment
Timeframe: Baseline to up to 60 months
Number of Participants Discontinuing AD Treatment
Timeframe: Baseline to up to 60 months
Number of Participants Switching AD Treatments
Timeframe: Baseline to up to 60 months
Number of Participants Augmenting AD treatment
Timeframe: Baseline to up to 60 months
Trial Transparency email recommended (Toll free for US & Canada)
Number of Participants Modifying AD Treatment Dose
Timeframe: Baseline to up to 60 months
Change from Baseline in Extent and Severity of AD Measured with Eczema Area and Severity Index (EASI)
Timeframe: Baseline to up to 60 months
Change from Baseline in Extent and Severity of AD Measured with Body Surface Area (BSA)
Timeframe: Baseline to up to 60 months
Change from Baseline in Extent and Severity of AD Measured with Validated Investigator's Global Assessment for Atopic Dermatitis (vIGA-AD)
Timeframe: Baseline to up to 60 months
Change from Baseline in Extent and Severity of AD Measured with Revised Investigator's Global Assessment for Atopic Dermatitis (rIGA-AD)
Timeframe: Baseline to up to 60 months
Change in Atopic Dermatitis Control Test (ADCT) from Baseline
Timeframe: Baseline to up to 60 months
Change in Patient Global Impression of Severity (PGIS) from Baseline
Timeframe: Baseline to up to 60 months
Change in Itch severity as Measured with the Peak Pruritus Numeric Rating Scale (PP-NRS) from Baseline
Timeframe: Baseline to up to 60 months
Change in Skin Pain as Measured with Skin Pain Numeric Rating Scale (SP-NRS) from Baseline
Timeframe: Baseline to up to 60 months
Change in Sleep Disturbance as Measured with Sleep Disturbance Numeric Rating Scale (SD-NRS) from Baseline
Timeframe: Baseline to up to 60 months
Remission of AD
Timeframe: Baseline to up to 60 months